Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of CSL's Influenza Vaccine in Healthy Adults
NCT00562484Phase 4Completed
- Sponsor
- CSL Seqirus
- Start
- Mar 2008
- Primary completion
- Nov 2009
- Modality
- Live Attenuated Vaccines, Whole Inactivated Vaccines
- Countries
- 2
01
Overview
Phase 4, randomised, double-blind trial in influenza comparing CSL Limited Influenza Vaccine with Placebo (2 arms). Primary endpoint: Overall Vaccine Efficacy (VE) Versus Placebo Through Assessment of Incidence of Laboratory Confirmed Influenza A/B Infection. Started Mar 2008; status: completed.
02
Drugs
standard dose influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT00562484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00562484.